
    
      In this placebo-controlled, blinded study, individuals with depression will participate in 2
      experimental sessions approximately 4 weeks apart during which they will receive two of the
      following three interventions: 1) placebo, 2) low dose psilocybin (0.1 mg/kg), and 3) medium
      dose psilocybin (0.3 mg/kg).
    
  